SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00542789

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use

The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating presence or absence of gastric and/or duodenal ulcers throughout the treatment period (24 weeks) in terms of efficacy on prevention of gastric and/or duodenal ulcers

NCT00542789 Gastric Ulcer Duodenal Ulcer Rheumatoid Arthritis Osteoarthritis Lumbago
MeSH:Stomach Ulcer Duodenal Ulcer Ulcer
HPO:Duodenal ulcer Gastric ulcer

2 Interventions

Name: Esomeprazole

Description: 20mg once daily oral
Type: Drug
Group Labels: 1

2

Name: Placebo

Description: once daily oral
Type: Drug
Group Labels: 1

1


Primary Outcomes

Description: The absence of gastric and/or duodenal ulcer throughout the treatment period

Measure: Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period

Time: each visit up to 24 weeks

Secondary Outcomes

Description: The absence of gastric and/or duodenal ulcer up to 4 weeks after treatment

Measure: Absence of Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment

Time: up to 4 weeks

Description: The absence of gastric and/or duodenal ulcer up to 12 weeks after treatment

Measure: Absence of Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment

Time: up to 12 weeks

Purpose: Prevention

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 D961H

Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating presence or absence of gastric and/or duodenal ulcers throughout the treatment period (24 weeks) in terms of efficacy on prevention of gastric and/or duodenal ulcers Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period. --- D961H ---



HPO Nodes


HPO: